Mirum Pharmaceuticals (MIRM) EBITDA (2019 - 2026)

Mirum Pharmaceuticals' EBITDA history runs 8 years deep, the most recent figure standing at -$789.5 million for Q1 2026.

• On a quarterly basis, EBITDA fell 5099.66% year-over-year to -$789.5 million in Q1 2026; TTM through Mar 2026 was -$796.4 million, a 943.51% decrease from a year earlier, with the FY2025 full-year figure at -$22.1 million, up 74.73% from the prior year.
• EBITDA retreated to -$789.5 million in Q1 2026 per MIRM's latest filing, from -$4.6 million in the prior quarter.
• Across five years, EBITDA topped out at $2.6 million in Q3 2025 and bottomed at -$789.5 million in Q1 2026.
• The 5-year median for EBITDA is -$25.1 million (2023), against an average of -$67.0 million.
• Across the five-year window, EBITDA surged 120.52% in 2025 and slumped 5099.66% in 2026, its largest moves.
• Year by year, EBITDA stood at -$34.2 million in 2022, then increased by 4.61% to -$32.6 million in 2023, then advanced by 25.67% to -$24.2 million in 2024, then soared by 81.15% to -$4.6 million in 2025, then slumped by 17186.29% to -$789.5 million in 2026.
• Per Business Quant, the three latest MIRM EBITDA figures stand at -$789.5 million (Q1 2026), -$4.6 million (Q4 2025), and $2.6 million (Q3 2025).